FUT6 and cancer: In other words, cancer types exhibiting higher FUT methylation are more sensitive to targeted therapies with the exception of FUT1 and FUT6 (Figure 1D), suggesting that cancer cells can inhibit fucosylation upon increased methylation of FUT promoter are more susceptible to therapy.